Compare · DFTX vs MTCR
DFTX vs MTCR
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Metacrine Inc. (MTCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MTCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 276.6x MTCR ($21.8M).
- DFTX has hit the wire 15 times in the past 4 weeks while MTCR has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 4 for MTCR).
- Company
- Definium Therapeutics Inc.
- Metacrine Inc.
- Price
- -
- -
- Market cap
- $6.02B
- $21.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 15
- 0
- Recent ratings
- 7
- 4
Metacrine Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Latest MTCR
- SEC Form 15-12G filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Klassen Preston
- SEC Form S-8 POS filed by Metacrine Inc.
- SEC Form S-8 POS filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Leadership Update
- Metacrine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets
- SEC Form EFFECT filed by Metacrine Inc.
- SEC Form 25-NSE filed by Metacrine Inc.
- SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)